Emricasan
http://dbpedia.org/resource/Emricasan an entity of type: Thing
Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010. Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization.
rdf:langString
rdf:langString
Emricasan
xsd:integer
52324749
xsd:integer
1084238793
xsd:integer
26
xsd:integer
254750
xsd:integer
10172707
xsd:integer
4
xsd:integer
27
xsd:integer
-3
rdf:langString
D10004
rdf:langString
Investigational New Drug
xsd:double
569.501
xsd:integer
3
xsd:integer
7
xsd:integer
12000240
rdf:langString
C[C@@H]NCCNc2ccccc2CC
xsd:integer
1
rdf:langString
SCVHJVCATBPIHN-SJCJKPOMSA-N
rdf:langString
P0GMS9N47Q
rdf:langString
Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010. Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization. The substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects. It was developed for the treatment of liver disease and has been granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis cirrhosis The substance is the first pan-caspase inhibitor to advance to broad clinical testing, and its novel mechanism of action has led to research using it for other potential applications.
xsd:nonNegativeInteger
6822
xsd:string
254750-02-2
xsd:string
P0GMS9N47Q
xsd:string
D10004
xsd:string
12000240